These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35095916)

  • 21. Corrigendum: Phenotypic alteration of low-density granulocytes in people with pulmonary post-acute sequelae of SARS-CoV-2 infection.
    Dean LS; Devendra G; Jiyarom B; Subia N; Tallquist MD; Nerurkar VR; Chang SP; Chow DC; Shikuma CM; Park J
    Front Immunol; 2023; 14():1209624. PubMed ID: 37187732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corrigendum: Antimicrobial resistance in the COVID-19 landscape: is there an opportunity for anti-infective antibodies and antimicrobial peptides?
    Pérez de la Lastra JM; Anand U; González-Acosta S; López MR; Dey A; Bontempi E; delaNuez AM
    Front Immunol; 2024; 15():1365827. PubMed ID: 38343533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome.
    Choreño-Parra JA; Jiménez-Álvarez LA; Ramírez-Martínez G; Sandoval-Vega M; Salinas-Lara C; Sánchez-Garibay C; Luna-Rivero C; Hernández-Montiel EM; Fernández-López LA; Cabrera-Cornejo MF; Choreño-Parra EM; Cruz-Lagunas A; Domínguez A; Márquez-García E; Cabello-Gutiérrez C; Bolaños-Morales FV; Mena-Hernández L; Delgado-Zaldivar D; Rebolledo-García D; Guadarrama-Ortiz P; Regino-Zamarripa NE; Mendoza-Milla C; García-Latorre EA; Rodríguez-Reyna TS; Cervántes-Rosete D; Hernández-Cárdenas CM; Khader SA; Zlotnik A; Zúñiga J
    Front Immunol; 2021; 12():700716. PubMed ID: 34054884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corrigendum: Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity.
    Razonable RR
    Front Immunol; 2024; 15():1440571. PubMed ID: 39119333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
    Kuhn C; Weiner HL
    Immunotherapy; 2016 Jul; 8(8):889-906. PubMed ID: 27161438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response.
    Hirzel C; Grandgirard D; Surial B; Wider MF; Leppert D; Kuhle J; Walti LN; Schefold JC; Spinetti T; Suter-Riniker F; Dijkman R; Leib SL
    Ther Adv Neurol Disord; 2022; 15():17562864221080528. PubMed ID: 35299779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corrigendum:
    Alizadeh M; Bavananthasivam J; Shojadoost B; Astill J; Taha-Abdelaziz K; Alqazlan N; Boodhoo N; Shoja Doost J; Sharif S
    Front Immunol; 2023; 14():1252523. PubMed ID: 37614236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Levels of Peripheral CD3
    Aljabr W; Al-Amari A; Abbas B; Karkashan A; Alamri S; Alnamnakani M; Al-Qahtani A
    Microbiol Spectr; 2022 Feb; 10(1):e0084521. PubMed ID: 35196808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corrigendum: Interferon-α2b Treatment for COVID-19.
    Zhou Q; Chen V; Shannon CP; Wei XS; Xiang X; Wang X; Wang ZH; Tebbutt SJ; Kollmann TR; Fish EN
    Front Immunol; 2020; 11():615275. PubMed ID: 33193462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 activates lung epithelial cell proinflammatory signaling and leads to immune dysregulation in COVID-19 patients.
    Chen H; Liu W; Wang Y; Liu D; Zhao L; Yu J
    EBioMedicine; 2021 Aug; 70():103500. PubMed ID: 34311326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
    Ozkaynak MF; Gilman AL; London WB; Naranjo A; Diccianni MB; Tenney SC; Smith M; Messer KS; Seeger R; Reynolds CP; Smith LM; Shulkin BL; Parisi M; Maris JM; Park JR; Sondel PM; Yu AL
    Front Immunol; 2018; 9():1641. PubMed ID: 30046297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corrigendum: Definition of the immune parameters related to COVID-19 severity.
    Birindelli S; Tarkowski MS; Gallucci M; Schiuma M; Covizzi A; Lewkowicz P; Aloisio E; Falvella FS; Dolci A; Riva A; Galli M; Panteghini M
    Front Immunol; 2023; 14():1219179. PubMed ID: 37292212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erratum: Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease.
    Frontiers Production Office
    Front Immunol; 2021; 12():733897. PubMed ID: 34326851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corrigendum: GSH-C4 Acts as Anti-inflammatory Drug in Different Models of Canonical and Cell Autonomous Inflammation Through NFκB Inhibition.
    Limongi D; Baldelli S; Checconi P; Marcocci ME; De Chiara G; Fraternale A; Magnani M; Ciriolo MR; Palamara AT
    Front Immunol; 2019; 10():1481. PubMed ID: 31333646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
    Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.
    Lai C; Liu X; Yan Q; Lv H; Zhou L; Hu L; Cai Y; Wang G; Chen Y; Chai R; Liu Z; Xu Y; Huang W; Xiao F; Hu L; Li Y; Huang J; Zhou Q; Li L; Peng T; Zhang H; Zhang Z; Chen L; Chen C; Ji T
    Front Immunol; 2021; 12():664619. PubMed ID: 34305895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corrigendum:
    Shim D; Kim H; Shin SJ
    Front Immunol; 2020; 11():1601. PubMed ID: 32765536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corrigendum: Complement activation via the lectin and alternative pathway in patients with severe COVID-19.
    Niederreiter J; Eck C; Ries T; Hartmann A; Märkl B; Buettner-Herold M; Amann K; Daniel C
    Front Immunol; 2023; 14():1294153. PubMed ID: 37809063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
    Shahini E; Pesce F; Argentiero A; Solimando AG
    Front Immunol; 2023; 14():1210147. PubMed ID: 37207235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.